Revision history of "Development of an oncological drug at reduced dose using modern technologies" (Q78546)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 October 2024

  • curprev 21:4321:43, 12 October 2024DG Regio talk contribs 86,989 bytes +5 Changed label, description and/or aliases in pt
  • curprev 21:4321:43, 12 October 2024DG Regio talk contribs 86,984 bytes −47 Set a claim value: summary (P836): O projeto resultará num medicamento inovador que contém acetato de abiraterona com maior biodisponibilidade para o medicamento de referência – Zytiga – as empresas Janssen-Cilag. A obtenção desse produto exigirá a utilização de tecnologias modernas e de I & D avançados. O projeto desenvolverá um medicamento significativamente melhorado que contenha uma dose mais baixa da substância ativa, o que melhorará a segurança do doente resultante da red...

20 March 2024

12 January 2024

6 July 2023

11 June 2023

24 May 2023

2 March 2023

25 October 2022

20 October 2022

13 August 2022

  • curprev 16:2416:24, 13 August 2022DG Regio talk contribs 80,972 bytes +51,723 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

19 January 2022

15 January 2022

16 December 2021

7 December 2021

30 November 2021

  • curprev 16:1716:17, 30 November 2021DG Regio talk contribs 17,711 bytes +2,847 Created claim: summary (P836): Le projet débouchera sur un médicament innovant contenant de l’acétate d’abiraterone avec une biodisponibilité accrue du médicament de référence — Zytiga – Janssen-Cilag. L’obtention d’un tel produit nécessitera l’utilisation de technologies modernes et de travaux de R-D de pointe. Le projet mettra au point un médicament considérablement amélioré, contenant une dose plus faible de la substance active, ce qui améliorera la sécurité du patie...
  • curprev 16:1716:17, 30 November 2021DG Regio talk contribs 14,864 bytes +158 Changed label, description and/or aliases in fr: translated_label

29 October 2020

14 October 2020

  • curprev 12:5212:52, 14 October 2020DG Regio talk contribs 15,146 bytes +135 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 12:5212:52, 14 October 2020DG Regio talk contribs 15,011 bytes −137 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 12:5212:52, 14 October 2020DG Regio talk contribs 15,148 bytes +2,586 Created claim: summary (P836): The project will result in an innovative medicine containing abiraterone acetate with increased bioavailability to the reference medicine – Zytiga – the Janssen-Cilag companies. Obtaining such a product will require the use of modern technologies and advanced R & D. The project will develop a significantly improved drug containing a lower dose of the active substance, which will improve the patient’s safety resulting from the reduction of...
  • curprev 12:5212:52, 14 October 2020DG Regio talk contribs 12,562 bytes −1,896 Removed claim: summary (P836): The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of...

25 September 2020

23 September 2020

17 July 2020

9 June 2020

6 June 2020

26 March 2020

4 March 2020

  • curprev 09:2209:22, 4 March 2020DG Regio talk contribs 12,740 bytes +1,896 Created claim: summary (P836): The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of ad...

18 February 2020

8 February 2020

31 January 2020

13 January 2020